Diabetic Retinopathy Market: Rising disposable income and fear of losing vision have increased the spending by patients to avail necessary treatmentDiabetic Equipment & SuppliesUpdated on May 3, 2019 View more like this | Visit ANCHORAGE, AK | Contact Market Data Forecast |
Market Overview:
The global diabetic retinopathy market size was valued at USD 5.81 billion in 2016 and is estimated to grow at a CAGR of 6.3% over the forecast period. Diabetic retinopathy is taken into account as a sight-threatening severe complication that results because of the long term diabetes. It is a disorder, inflicting progressive harm to the retina and affecting the retinal circulatory system. The treatment line choice for diabetic retinopathy depends on the extremity of the condition and may require intraocular injections, anti-VEGF medication, laser surgery or vitrectomy. Increasing prevalence of diabetes in conjunction with a growing incidence of blindness because of diabetes is estimated to propel the market growth over the forecast period. According to the estimates of the WHO, the range of individuals with diabetes has inflated from 108 million adults in 1980 to around 422 million adults in 2014. Additionally, the global prevalence of diabetes has also doubled, at nearly 8.5% in the adult population in 2014, as compared to 4.7% in 1980.
Market Drivers and Restraints:
About 78.0% of cases of diabetic retinopathy were reported in 2013, as per the statistics are given by the Department of Assistive and Rehabilitative Services (DARS), Texas that could eventually cause loss of vision. As per the Royal National Institute of Blind People (RNIB), diabetic retinopathy was amongst the ruling causes of blindness in UK in 2017. Growing disposable income and the fear of losing vision have inflated the spending by patients to avail significant treatment. Availability of advanced technology and minimal pain inducing laser procedure with quick recovery is expected to promote patients’ disposition to adopt surgical treatments.
To know more, click on the link below:
https://marketdataforecast.com/market-reports/diabetic-retinopathy-market-936/
Report segmented as:
By Type of Treatment:
Anti-Vascular Endothelial Growth Factor (VEGF) drug
Intraocular Steroid Injection
Laser Surgery
Vitrectomy
By Indication:
Non-Proliferative Diabetic Retinopathy (NPDR)
Mild
Moderate
Severe
Proliferative Diabetic Retinopathy (PDR)
By End Users:
Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers
Geographical Analysis:
North America region accounted for the biggest share owing to the supportive reimbursement policies, and increasing prevalence of diabetes. High market penetration of Avastin, Eylea, and Lucentis which are anti-VEGF drugs, is one of the major factors contributing to the large regional share. Europe commanded the second most significant share in the diabetic retinopathy market in 2016. The growing healthcare infrastructure in conjunction with favorable compensation framework in the developed European countries is estimated to propel the market growth during the forecast period. The emerging nations such as Japan and China in the Asia Pacific are expected to witness moneymaking growth throughout the forecast period owing to increasing disposable income, increasing geriatric population, expanding research funding for diabetes, innovation in diagnostics, and large target patient pool. China’s market is expected to witness rapid growth over the forecast period. Japan is the largest market in the Asia Pacific region mainly on account of the presence of high healthcare expenditure and rising disposable income.
Important Market Players:
The global market is consolidated in nature and is extremely competitive due to the presence of a large number of players. The major players are Novartis AG, Bayer Healthcare, Regeneron Pharmaceuticals Inc., ThromboGenics, Actavis Plc., Sirnaomics, Genentech, Alimera Sciences, Glycadia Pharmaceuticals, Ampio Pharmaceuticals, Kowa Group, and BCN Peptides. Companies are adopting strategic initiatives such as acquisitions, mergers, geographical expansion, and product development to advance their businesses and increase their outreach in the market. For instance, ThromboGenics initiated a partnership with Novartis (Alcon) to assist in the marketing and commercialization of JETREA outside the U.S.
View a sample and decide @ https://marketdataforecast.com/market-reports/diabetic-retinopathy-market-936/request-sample
The Scope of the report:
This report offers the current product and services market evaluation and the future estimation of the market. It helps us understand the market better through size anticipation and CAGR calculation to estimate the next market. It has a broader segmentation for better understanding of the enterprising of the market at a low level by segregating the market into smaller sectors.
About Us:
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.
For more information:
Abhishek Shukla
Sales Manager at Market Data Forecast
Email: [email protected]
Tel: +1-888-702-9626
Website: https://www.marketdataforecast.com/
The global diabetic retinopathy market size was valued at USD 5.81 billion in 2016 and is estimated to grow at a CAGR of 6.3% over the forecast period. Diabetic retinopathy is taken into account as a sight-threatening severe complication that results because of the long term diabetes. It is a disorder, inflicting progressive harm to the retina and affecting the retinal circulatory system. The treatment line choice for diabetic retinopathy depends on the extremity of the condition and may require intraocular injections, anti-VEGF medication, laser surgery or vitrectomy. Increasing prevalence of diabetes in conjunction with a growing incidence of blindness because of diabetes is estimated to propel the market growth over the forecast period. According to the estimates of the WHO, the range of individuals with diabetes has inflated from 108 million adults in 1980 to around 422 million adults in 2014. Additionally, the global prevalence of diabetes has also doubled, at nearly 8.5% in the adult population in 2014, as compared to 4.7% in 1980.
Market Drivers and Restraints:
About 78.0% of cases of diabetic retinopathy were reported in 2013, as per the statistics are given by the Department of Assistive and Rehabilitative Services (DARS), Texas that could eventually cause loss of vision. As per the Royal National Institute of Blind People (RNIB), diabetic retinopathy was amongst the ruling causes of blindness in UK in 2017. Growing disposable income and the fear of losing vision have inflated the spending by patients to avail significant treatment. Availability of advanced technology and minimal pain inducing laser procedure with quick recovery is expected to promote patients’ disposition to adopt surgical treatments.
To know more, click on the link below:
https://marketdataforecast.com/market-reports/diabetic-retinopathy-market-936/
Report segmented as:
By Type of Treatment:
Anti-Vascular Endothelial Growth Factor (VEGF) drug
Intraocular Steroid Injection
Laser Surgery
Vitrectomy
By Indication:
Non-Proliferative Diabetic Retinopathy (NPDR)
Mild
Moderate
Severe
Proliferative Diabetic Retinopathy (PDR)
By End Users:
Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers
Geographical Analysis:
North America region accounted for the biggest share owing to the supportive reimbursement policies, and increasing prevalence of diabetes. High market penetration of Avastin, Eylea, and Lucentis which are anti-VEGF drugs, is one of the major factors contributing to the large regional share. Europe commanded the second most significant share in the diabetic retinopathy market in 2016. The growing healthcare infrastructure in conjunction with favorable compensation framework in the developed European countries is estimated to propel the market growth during the forecast period. The emerging nations such as Japan and China in the Asia Pacific are expected to witness moneymaking growth throughout the forecast period owing to increasing disposable income, increasing geriatric population, expanding research funding for diabetes, innovation in diagnostics, and large target patient pool. China’s market is expected to witness rapid growth over the forecast period. Japan is the largest market in the Asia Pacific region mainly on account of the presence of high healthcare expenditure and rising disposable income.
Important Market Players:
The global market is consolidated in nature and is extremely competitive due to the presence of a large number of players. The major players are Novartis AG, Bayer Healthcare, Regeneron Pharmaceuticals Inc., ThromboGenics, Actavis Plc., Sirnaomics, Genentech, Alimera Sciences, Glycadia Pharmaceuticals, Ampio Pharmaceuticals, Kowa Group, and BCN Peptides. Companies are adopting strategic initiatives such as acquisitions, mergers, geographical expansion, and product development to advance their businesses and increase their outreach in the market. For instance, ThromboGenics initiated a partnership with Novartis (Alcon) to assist in the marketing and commercialization of JETREA outside the U.S.
View a sample and decide @ https://marketdataforecast.com/market-reports/diabetic-retinopathy-market-936/request-sample
The Scope of the report:
This report offers the current product and services market evaluation and the future estimation of the market. It helps us understand the market better through size anticipation and CAGR calculation to estimate the next market. It has a broader segmentation for better understanding of the enterprising of the market at a low level by segregating the market into smaller sectors.
About Us:
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.
For more information:
Abhishek Shukla
Sales Manager at Market Data Forecast
Email: [email protected]
Tel: +1-888-702-9626
Website: https://www.marketdataforecast.com/
